Skip to main content

Advertisement

SpringerLink
Log in

MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

Chemoradiotherapy is the standard treatment modality for advanced non-small cell lung cancer (NSCLC). However, drug and radiation resistance remain major factors influencing its clinical outcome. The purpose of this study was to evaluate whether MDMX can affect the chemosensitivity and clinical outcome of NSCLC.

Methods

Quantitative real-time PCR (qRT-PCR) was performed to assess MDMX mRNA expression levels in 105 primary NSCLC tissues, its corresponding non-cancerous tissues and two NSCLC-derived cell lines (A549 and SK-MES-1). In addition, immunohistochemistry was carried out to detect MDMX protein expression in the primary NSCLC tissues. The MDMX expression levels were correlated with clinicopathological and survival features. The effects of MDMX expression knockdown on NSCLC cell proliferation and chemosensitivity were evaluated using MTT, flow cytometry and soft agar colony assays.

Results

We found that the mRNA expression level of MDMX in NSCLC tissues was significantly higher than that in its corresponding non-tumorous tissues. High MDMX expression was found to be related to poor tumor cell differentiation, advanced TNM stages and the occurrence of lymph node metastases. Patients with a high MDMX expression level exhibited a lower overall survival rate than those with a low expression level. Multivariate analysis showed that a high MDMX protein expression level may serve as an independent prognostic factor for NSCLC patients. In addition, we found that MDMX expression knockdown combined with cisplatin treatment in vitro significantly increased apoptosis and decreased soft agar colony formation in NSCLC-derived cells.

Conclusions

Our data indicate that MDMX expression may serve as an independent unfavorable prognostic factor for NSCLC patient outcome, which in turn may at least partly be due to the ability of the MDMX protein to regulate the proliferative capacity and chemosensitivity of NSCLC cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, A. Jemal, Cancer treatment and survivorship statistics. CA Cancer J Clin 64, 252–271 (2014)

  2. M. Reck, D.F. Heigener, T. Mok, J.C. Soria, K.F. Rabe, Management of non-small-cell lung cancer: Recent developments. Lancet 382, 709–719 (2013)

    Article  CAS  PubMed  Google Scholar 

  3. L.E. Coate, T. John, M.S. Tsao, F.A. Shepherd, Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10, 1001–1010 (2009)

    Article  CAS  PubMed  Google Scholar 

  4. Y.X. Bao, X.D. Zhao, H.B. Deng, C.L. Lu, Y. Guo, X. Lu, L.L. Deng, Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations. Cell Oncol 39, 343–352 (2016)

    Article  CAS  Google Scholar 

  5. C.C. Koning, S.J. Wouterse, J.G. Daams, L.L. Uitterhoeve, M.M. van den Heuvel, J.S. Belderbos, Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: A systematic review of the literature. Clin Lung Cancer 14, 481–487 (2013)

    Article  CAS  PubMed  Google Scholar 

  6. P. Chen, J. Li, Y.C. Chen, H. Qian, Y.J. Chen, J.Y. Su, M. Wu, T. Lan, The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cell Oncol 39, 511–522 (2016)

    Article  Google Scholar 

  7. Y.L. Chen, T.Y. Yang, K.C. Chen, C.L. Wu, S.L. Hsu, C.M. Hsueh, Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Cell Oncol 39, 411–433 (2016)

  8. R. Shavit, M. Ilouze, T. Feinberg, Y.R. Lawrence, Y. Tzur, N. Peled, Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report. Cell Oncol 39, 247–252 (2015)

    Article  Google Scholar 

  9. A. Shvarts, W.T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R.C. van Ham, W. van der Houven van Oordt, G. Hateboer, A.J. van der Eb, A.G. Jochemsen, MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J 15, 5349–5357 (1996)

    CAS  PubMed  PubMed Central  Google Scholar 

  10. R. Stad, Y.F. Ramos, N. Little, S. Grivell, J. Attema, A.J. van Der Eb, A.G. Jochemsen, Hdmx stabilizes Mdm2 and p53. J Biol Chem 275, 28039–28044 (2000)

    CAS  PubMed  Google Scholar 

  11. J.C. Marine, A.G. Jochemsen, Mdmx and Mdm2: Brothers in arms. Cell Cycle 3, 900–904 (2004)

    Article  CAS  PubMed  Google Scholar 

  12. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, J.C. Marine, Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24, 5835–5843 (2004)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. H. Wang, C. Yan, A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13, 611–619 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. M.J. Riemenschneider, C.B. Knobbe, G. Reifenberger, Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 104, 752–757 (2003)

    Article  CAS  PubMed  Google Scholar 

  15. X. Han, G. Garcia-Manero, T.J. McDonnell, G. Lozano, L.J. Medeiros, L. Xiao, G. Rosner, M. Nguyen, M. Fernandez, Y.A. Valentin-Vega, J. Barboza, D.M. Jones, G.Z. Rassidakis, H.M. Kantarjian, C.E. Bueso-Ramos, HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20, 54–62 (2007)

    Article  CAS  PubMed  Google Scholar 

  16. Y.A. Valentin-Vega, J.A. Barboza, G.P. Chau, A.K. El-Naggar, G. Lozano, High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38, 1553–1562 (2007)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. T. Sun, G.S. Lee, W.K. Oh, M. Pomerantz, M. Yang, W. Xie, M.L. Freedman, P.W. Kantoff, Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 16, 5244–5251 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. R. Tirabosco, G. De Maglio, M. Skrap, G. Falconieri, S. Pizzolitto, Expression of the Polycomb-group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases. Pathol Res Pract 204, 625–631 (2008)

    Article  PubMed  Google Scholar 

  19. D. Li, D.Q. Li, D. Liu, X.J. Tang, MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol 39, 139–147 (2016)

    Article  CAS  Google Scholar 

  20. F. Toledo, G.M. Wahl, MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39, 1476–1482 (2007)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Q. Li, G. Lozano, Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 19, 34–41 (2013)

    Article  PubMed  Google Scholar 

  22. J. Parant, A. Chavez-Reyes, N.A. Little, W. Yan, V. Reinke, A.G. Jochemsen, G. Lozano, Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway withMDM2 to regulate p53. Nat Genet 29, 92–95 (2001)

    Article  CAS  PubMed  Google Scholar 

  23. G. Jin, S. Cook, B. Cui, W.C. Chen, S.T. Keir, P. Killela, C. Di, C.A. Payne, S.G. Gregory, R. McLendon, D.D. Bigner, H. Yan, HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology 12, 956–966 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. S. Haupt, D. Buckley, J.M. Pang, J. Panimaya, P.J. Paul, C. Gamell, E.A. Takano, Y.Y. Lee, S. Hiddingh, T.M. Rogers, A.F. Teunisse, M.J. Herold, J.C. Marine, S.B. Fox, A. Jochemsen, Y. Haupt, Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis 6, e1821 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. K. Heminger, M. Markey, M. Mpagi, S.J. Berberich, Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53. Aging 1, 89–108 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Q. Yu, Y. Li, K. Mu, Z. Li, Q. Meng, X. Wu, Y. Wang, L. Li, Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol 9, 71 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  27. L. Marcar, B. Ihrig, J. Hourihan, S.E. Bray, P.R. Quinlan, L.B. Jordan, A.M. Thompson, T.R. Hupp, D.W. Meek, MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4. PLoS One 10, e0127713 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  28. A.M. Carrillo, A. Bouska, M.P. Arrate, C.M. Eischen, Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34, 846–856 (2015)

    Article  CAS  PubMed  Google Scholar 

  29. M.P. Markey, Regulation of MDM4. Front Biosci 16, 1144–1156 (2011)

    Article  CAS  Google Scholar 

  30. M. Shadfan, V. Lopez-Pajares, Z.M. Yuan, MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1, 88–89 (2012)

    PubMed  PubMed Central  Google Scholar 

  31. V. Sulzyc-Bielicka, P. Domagala, D. Bielicki, K. Safranow, W. Domagala, Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy. Cell Oncol 37, 17–28 (2014)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China(No. 81201803).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, 110022, China

    Han Zhao, Yu-Zhuo Xie, Rui Xing, Feng Chi & Yue-Can Zeng

  2. Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, China

    Ming Sun

Authors
  1. Han Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Zhuo Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Feng Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yue-Can Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yue-Can Zeng.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, H., Xie, YZ., Xing, R. et al. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin. Cell Oncol. 40, 357–365 (2017). https://doi.org/10.1007/s13402-017-0325-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-017-0325-9

Keywords

Search

Navigation